Q3 FY2026 · ended Sep 30, 2026 · Revenue $13.07B, +6.9% YoY · Filed Oct 29, 2026
Bristol-Myers Squibb Company (BMY) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $13.1 billion and net income of $2.2 billion. Free cash flow was $3.8 billion. As of Sep 30, 2026 it held $13.0 billion in cash and investments and $45.6 billion in total debt.
Revenue
$13.07B
+6.9% vs year-ago quarter
Net income
$2.16B
-1.8% vs year-ago quarter
Operating cash flow
$4.18B
-33.8% vs year-ago quarter
Free cash flow
$3.84B
-36.0% vs year-ago quarter
EPS
$1.05
-2.8% vs year-ago quarter
Dividend per share
$0.63
+1.6% vs year-ago quarter
Shares outstanding
2.04B
+0.4% vs year-ago quarter
Net cash
$-32.62B
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BMY (NYSE), CELG-RI (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 14272
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $13.1B | $13.0B | $11.5B | $12.5B | $12.2B |
| Net income | $2.2B | $3.3B | $2.7B | $1.1B | $2.2B |
| Diluted EPS | $1.05 | $1.62 | $1.31 | $0.53 | $1.08 |
| Operating cash flow | $4.2B | $3.4B | $1.1B | $2.0B | $6.3B |
| Free cash flow | $3.8B | $3.1B | $757.0M | $1.6B | $6.0B |
| Total assets | $88.8B | $87.6B | $86.5B | $90.0B | $96.9B |
| Total liabilities | $65.4B | $65.3B | $66.4B | $71.5B | $78.3B |
| Stockholders' equity | $23.4B | $22.3B | $20.1B | $18.5B | $18.6B |
| Cash and investments | $13.0B | $11.5B | $10.9B | $11.1B | $16.9B |
| Total debt | $45.6B | $45.8B | $48.4B | $49.1B | $55.3B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 8, 2026 | May 5, 2026 |
| 10-Q | Quarterly report | Apr 30, 2026 | Mar 31, 2026 |
All 1003 Bristol-Myers Squibb Company SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.